Understanding molecular testing uptake across tumor types in eight countries: Results from a multinational cross-sectional survey

Pinkie Chambers, Kenneth K.C. Man, Vivian W.Y. Lui, Sheila Mpima, Paola Nasuti, Martin D. Forster, Ian C.K. Wong

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

PURPOSE The growth in understanding of molecular biology and genomics has augmented the development of targeted cancer treatments; however, challenges exist in access to molecular testing, an essential precursor to treatment decision-making. We used data from a cross-sectional survey to evaluate the differences in uptake of molecular testing, METHODS Using the aggregated results of a questionnaire developed and distributed to clinicians by IQVIA, including treatment details and investigations undertaken for patients, we compared proportions of patients receiving molecular testing and targeted treatment by cancer type for the United Kingdom, France, Italy, Germany, Spain, South Korea, Japan, and China. We used multivariable logistic regression methods to understand the effect of country on the odds of receiving a molecular test. RESULTS There was a total of 61,491 cases. Across countries and cancer types, uptake rates for molecular testing ranged between 2% and 98%, with the greatest differences seen in gastric cancers (range, 23% to 70%), and significant variations were observed for both European and Asian countries. China consistently demonstrated a significantly reduced uptake for all molecular tests assessed; however; uptake of drug treatment in gastric cancers after testing positive for the human epidermal growth factor receptor 2 gene was higher than in some European countries (China, 85%; European range, 8% to 66%). The uptake of epidermal growth factor receptor gene testing was greater in some Asian countries relative to the United Kingdom, where incidence of lung cancer is higher (Japan: odds ratio, 3.1 [95% CI, 2.6 to 3.8]; South Korea: odds ratio, 2.7 [95% CI, 2 to 3.4]). CONCLUSION We have highlighted inequity in access to molecular testing and subsequent treatments across countries, which warrants improvements.

Original languageEnglish (US)
Pages (from-to)E770-E778
JournalJCO Oncology Practice
Volume16
Issue number8
DOIs
StatePublished - 2020
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Health Policy
  • Oncology(nursing)

Fingerprint

Dive into the research topics of 'Understanding molecular testing uptake across tumor types in eight countries: Results from a multinational cross-sectional survey'. Together they form a unique fingerprint.

Cite this